Opana Related Published Studies
Well-designed clinical trials related to Opana (Oxymorphone)
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. [2010.11]
Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. [2010.05]
The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
Comparison of the analgesic efficacy of hydromorphone and oxymorphone in dogs and cats: a randomized blinded study. [2008.07]
Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial. [2007.06]
Efficacy and Safety of OPANA ER (Oxymorphone Extended Release) for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients: A 12-Week, Randomized, Double-blind, Placebo-controlled Study. [2007.02]
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. [2007.01]
A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. [2006.03]
Effects of oxymorphone and hydromorphone on the minimum alveolar concentration of isoflurane in dogs. [2006.01]
Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: results of a randomized, double-blind, placebo-controlled trial. [2005.12]
Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial. [2005.09]
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. [2005.03]
Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. [2005.01]
Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. [2005]
The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. [2004.11]
Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. [2004.07]
Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. [2004.06]
Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. [2004.04]
Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs. [2004.04]
Comparison of the effects of buprenorphine, oxymorphone hydrochloride, and ketoprofen for postoperative analgesia after onychectomy or onychectomy and sterilization in cats. [2002.11]
Effects of hydromorphone or oxymorphone, with or without acepromazine, on preanesthetic sedation, physiologic values, and histamine release in dogs. [2001.04.01]
Cardiovascular effects of epidurally administered oxymorphone and an oxymorphone-bupivacaine combination in halothane-anesthetized dogs. [1999.02]
End tidal halothane concentration and postoperative analgesia requirements in dogs: a comparison between intravenous oxymorphone and epidural bupivacaine alone and in combination with oxymorphone. [1998.06]
Comparison of ketoprofen, oxymorphone hydrochloride, and butorphanol in the treatment of postoperative pain in dogs. [1997.08.15]
A comparison of ketorolac with flunixin, butorphanol, and oxymorphone in controlling postoperative pain in dogs. [1996.09]
Ability of flumazenil, butorphanol, and naloxone to reverse the anesthetic effects of oxymorphone-diazepam in dogs. [1996.08.15]
Postoperative analgesic and cardiopulmonary effects in dogs of oxymorphone administered epidurally and intramuscularly, and medetomidine administered epidurally: a comparative clinical study. [1996.07]
Butorphanol tartrate for partial reversal of oxymorphone-induced postoperative respiratory depression in the dog. [1994.01]
Narcotic-induced histamine release: a comparison of morphine, oxymorphone, and fentanyl infusions. [1991.10]
An evaluation of morphine and oxymorphone administered via patient-controlled analgesia (PCA) or PCA plus basal infusion in postcesarean-delivery patients. [1989.10]
A comparison of morphine, meperidine, and oxymorphone as utilized in patient-controlled analgesia following cesarean delivery. [1989.04]
A comparison of oxymorphone and fentanyl as narcotic supplements in general anesthesia. [1989]
Well-designed clinical trials possibly related to Opana (Oxymorphone)
Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. [2011.03]
Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. [2011.01]
Grapefruit juice enhances the exposure to oral oxycodone. [2010.10]
Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. [2009.06]
The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. [2009.04]
Voriconazole drastically increases exposure to oral oxycodone. [2009.03]
The effect of single-dose tramadol on oxycodone clearance. [2007.11]
A synthetic fraction of feline facial pheromones calms but does not reduce struggling in cats before venous catheterization. [2006.07]
Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. [2006]
Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs. [2004.01]
Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. [2001.05]
Assessing the efficacy of perioperative carprofen administration in dogs undergoing surgical repair of a ruptured cranial cruciate ligament. [2000.09]
Morphine or oxycodone in cancer pain? [2000]
Comparison of ketoprofen and carprofen administered prior to orthopedic surgery for control of postoperative pain in dogs. [1999.10.15]
Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. [1998.12]
A comparison of ketorolac tromethamine/oxycodone versus patient-controlled analgesia with morphine in anterior cruciate ligament reconstruction patients. [1998.11]
Pharmacokinetics and pharmacodynamics of controlled-release opioids. [1997.01]
Epidural administration of bupivacaine, morphine, or their combination for postoperative analgesia in dogs. [1996.08.01]
Does naloxone cause a positive urine opiate screen? [1994.12]
Evaluation of anesthetic protocols for neutering 6- to 14-week-old pups. [1994.07.15]
Cardiorespiratory effects of four opioid-tranquilizer combinations in dogs. [1994.07]
Analgesia in dogs after intercostal thoracotomy: a clinical trial comparing intravenous buprenorphine and interpleural bupivacaine. [1994.07]
Respiratory effects and tolerability of Mr 2264 Cl. A new opiate partial agonist in comparison with morphine and placebo. [1994]
The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. [1992.06]
Epidural analgesia during and after cesarean delivery. Comparison of five opioids. [1991.03]
Subcutaneous-PCA: an alternative to IV-PCA for postoperative pain management. [1990.12]
Outpatient premedication: use of midazolam and opioid analgesics. [1989.10]
Other research related to Opana (Oxymorphone)
A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets. [2011.06]
Pharmacokinetics of oxymorphone in titi monkeys (Callicebus spp.) and rhesus macaques (Macaca mulatta). [2011.03]
Positive and negative subjective effects of extended-release oxymorphone versus
controlled-release oxycodone in recreational opioid users. [2011]
Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis. [2010.08]
Negligible analgesic tolerance seen with extended release oxymorphone: a post hoc analysis of open-label longitudinal data. [2010.08]
A systematic review of oxymorphone in the management of chronic pain. [2010.02]
Reduced cognitive and psychomotor impairment with extended-release oxymorphone
versus controlled-release oxycodone. [2010]
Long-term tolerability and effectiveness of oxymorphone extended release in
patients with cancer. [2010]
Factors affecting acceptability of titrated oxymorphone extended release in
chronic low back pain - an individual patient analysis. [2010]
A systematic review of oxymorphone in the management of chronic pain. [2010]
Case report: Oxymorphone-involved fatalities: a report of two cases. [2009.11]
Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. [2009.10]
Considerations on the use of oxymorphone in geriatric patients. [2009.09]
Pharmacokinetics and behavioral effects of an extended-release, liposome-encapsulated preparation of oxymorphone in rhesus macaques. [2009.07]
Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain. [2008.10]
Oxymorphone: a mature molecule with new life. [2008.10]
Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. [2008.05]
Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. [2008.05]
Comparison of the analgesic efficacy of hydromorphone and oxymorphone in dogs and cats: a randomized blinded study. [2008.03.18]
Oral extended-release oxymorphone: a new choice for chronic pain relief. [2007.07]
Oral oxymorphone for pain management. [2007.07]
Use of oral oxymorphone in the elderly. [2007.05]
Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. [2007.04.01]
Evidence that oxymorphone-induced increases in micronuclei occur secondary to hyperthermia. [2007.02]
Other possibly related research studies
Extended-duration agents for perioperative pain management. [2007.02]
Effectiveness of opioids in the treatment of chronic non-cancer pain. [2008.03]
The detection of hydromorphone in urine specimens with high morphine concentrations. [2008.05]
Methylnaloxone suppresses the development of withdrawal syndrome in morphine-dependent rats. [2007.05]
Activation of kappa-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: role of protein kinase C and K(ATP) channels. [2007.02]
Determination of opioid analgesics in hair samples using liquid chromatography/tandem mass spectrometry and application to patients under palliative care. [2007.10]
Method for quantification of opioids and their metabolites in autopsy blood by liquid chromatography-tandem mass spectrometry. [2007.09]
Nociception increases during opioid infusion in opioid receptor triple knock-out mice. [2007.06.29]
Oxycodone: a pharmacological and clinical review. [2007.05]
Voriconazole drastically increases exposure to oral oxycodone. [2008.10.03]
Current developments in opioid therapy for management of cancer pain. [2008.05]
Oral or transdermal opioids for osteoarthritis of the knee or hip. [2009.10.07]
Hypothesis on reciprocal interactions between the central and peripheral components of the endogenous opioid system. [2008.12]
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. [2009.07]
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. [2010.10]
Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. [2010.07]
|
